Closing the door on flaviviruses: Entry as a target for antiviral drug design
about
Molecular targets for flavivirus drug discoveryMechanism and significance of cell type-dependent neutralization of flavivirusesDengue Fever: Causes, Complications, and Vaccine StrategiesFlaviviruses: braking the enteringRole of microparticles in dengue virus infection and its impact on medical intervention strategiesZika virus: a new arboviral public health problemFocus on flaviviruses: current and future drug targetsTowards peptide vaccines against Zika virus: Immunoinformatics combined with molecular dynamics simulations to predict antigenic epitopes of Zika viral proteinsAn analogue of the antibiotic teicoplanin prevents flavivirus entry in vitroDengue-3 Virus Entry into Vero Cells: Role of Clathrin-Mediated Endocytosis in the Outcome of InfectionInhibitors compounds of the flavivirus replication processProbing the mechanism of pH-induced large-scale conformational changes in dengue virus envelope protein using atomistic simulations.Prediction of protein-protein interactions in dengue virus coat proteins guided by low resolution cryoEM structures.Novel approaches to flavivirus drug discovery.Differential requirements in endocytic trafficking for penetration of dengue virus.A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain.Serial femtosecond X-ray diffraction of enveloped virus microcrystalsDENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: A potential antiviral target.High-speed fixed-target serial virus crystallography.Japanese encephalitis virus infects porcine kidney epithelial PK15 cells via clathrin- and cholesterol-dependent endocytosis.West Nile virus: A re-emerging pathogen revisited.West Nile virus drug discovery.Potential of carbohydrate-binding agents as therapeutics against enveloped viruses.The human antibody response to dengue virus infectionGeneration and characterization of a monoclonal antibody against duck Tembusu virus envelope protein.A tripeptide (NSK) inhibits Japanese encephalitis virus infection in vitro and in vivo.Ultrastructural morphogenesis of salmonid alphavirus 1.Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development.Inactivation of Dengue and Yellow Fever viruses by heme, cobalt-protoporphyrin IX and tin-protoporphyrin IX.Identification of sequence motifs involved in Dengue virus-host interactions.New pockets in dengue virus 2 surface identified by molecular dynamics simulation.Computational identification of self-inhibitory peptides from envelope proteins.Dengue virus entry as target for antiviral therapy.Geraniin extracted from the rind of Nephelium lappaceum binds to dengue virus type-2 envelope protein and inhibits early stage of virus replication.Zika Virus: An Emerging Global Health Threat.Biochemistry and Molecular Biology of Flaviviruses.
P2860
Q21999123-073D43AF-7DE0-44D0-8733-ED6A9C03FCD1Q23032973-741704C4-57FF-4EBF-8763-B032D533EAFBQ26700082-B7D23AD7-3D5A-4999-A844-E00ACB7D370AQ26852435-F77822A2-129C-442A-99B1-E44DC3C17461Q26860307-042B3444-5A29-4CD9-8EC9-385C833F739FQ27010616-4ECC4338-71F7-46C0-B62C-C4C84474A9DBQ27490926-E24EFFB4-AF2B-4E92-BBFE-362935879391Q28119724-B01473CD-99B1-4867-A682-79E475DF26D3Q28483817-7DEC11E4-9248-4D33-97FF-6D1129458C18Q28550303-520FD715-436A-40AF-B645-65976A421530Q29994474-5C9BB190-B4EA-4B14-BD8E-22EAF8E1B824Q30391602-51492403-7AFB-4788-AED6-0592D6518C6DQ33605451-4E703991-1C8F-4064-8A64-1A0F4A0544C4Q34206832-4269099C-7EC1-472E-BB51-4D907D8023BEQ34412820-C69EE313-2D19-4DEA-9462-1768DE3C4A93Q35881790-89716279-B130-4FD5-BC37-09006D49FA2FQ35901032-621ACF3D-0A0F-4AA8-B8B3-3BAE67540A26Q36338285-62FC1102-C037-4928-B91F-23B82B1121ACQ36409005-A56A10AA-126C-4ABF-A18A-36EB9AD74B4AQ37114619-0F67CE82-649E-4585-B211-CBC9C22530E9Q37195527-7D7B4BD3-E68C-46A0-B99C-0B069AF14890Q37666750-DCD77567-CEBD-4F66-8C91-FEC1D9E111E6Q37767654-616B9FB4-FF41-4C44-8D97-749D30AD6B49Q37987124-422AFC33-7966-4046-A0F0-B2D72B5618EAQ38721146-30B811EF-B190-4021-A388-8FAECD21BF71Q39051535-A3BEBB88-A992-4EB0-BE52-87EF44E46E4DQ39293003-0AA3B4A3-CFFF-4A12-B972-A6355E0498CEQ39535403-9DC34515-B657-4844-9FEC-14E5A3C5568DQ40123101-9F9D2BBC-8C15-4326-AD5B-79679C77151EQ40159006-0684A821-5837-46B5-9F5E-2E2BB9FEE4ABQ40266244-1914971E-D68A-451F-8F3E-AC6C3108BFFEQ40288667-8DAB9348-C23B-4C3A-A50B-A5EBB6BDA9F4Q40289267-6F810CAA-3BFF-4CD6-862C-EFA484461519Q45324483-2CA42249-76E3-4FCA-B30A-FBBA843889F4Q47130545-562042A0-B820-4EF9-BFFC-14438C1C0A30Q55277816-B3CB13C6-54B3-4DF3-9CCC-618810B57FDC
P2860
Closing the door on flaviviruses: Entry as a target for antiviral drug design
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Closing the door on flaviviruses: Entry as a target for antiviral drug design
@ast
Closing the door on flaviviruses: Entry as a target for antiviral drug design
@en
Closing the door on flaviviruses: Entry as a target for antiviral drug design
@nl
type
label
Closing the door on flaviviruses: Entry as a target for antiviral drug design
@ast
Closing the door on flaviviruses: Entry as a target for antiviral drug design
@en
Closing the door on flaviviruses: Entry as a target for antiviral drug design
@nl
prefLabel
Closing the door on flaviviruses: Entry as a target for antiviral drug design
@ast
Closing the door on flaviviruses: Entry as a target for antiviral drug design
@en
Closing the door on flaviviruses: Entry as a target for antiviral drug design
@nl
P2860
P3181
P1433
P1476
Closing the door on flaviviruses: Entry as a target for antiviral drug design
@en
P2093
Mansoora Khaliq
Rushika Perera
P2860
P3181
P356
10.1016/J.ANTIVIRAL.2008.05.004
P50
P577
2008-10-01T00:00:00Z